A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations

Cited by (644)

Items 201–300 of 644

1. Ginsenoside CK induces apoptosis and suppresses proliferation and invasion of human osteosarcoma cells through the PI3K/mTOR/p70S6K1 pathway
   Kang Chen, Jianbao Jiao, Jinwei Xue, Taoping Chen, Yu Hou, Yuan-Tao Jiang, Ligang Qian, Yunfei Wang, Zheng Ma, Zhixing Liang et al. · 2020 · Oncology Reports
2. Cinobufagin Triggers Defects in Spindle Formation and Cap-Dependent Translation in Liver Cancer Cells by Inhibiting the AURKA-mTOR-eIF4E Axis
   Xiaohan Jin, Jiabao Wang, Shuang Zou, Rui‐Cheng Xu, Jin Cao, Yan Zhang, Jia Guo, Xiaochang Wen, Sanmin Deng, Yupiao Zheng et al. · 2020 · The American Journal of Chinese Medicine
3. Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma
   Md Gulam Musawwir Khan, Amit Ghosh, Bhavesh C. Variya, Madanraj Appiya Santharam, Awais Ullah Ihsan, Sheela Ramanathan, Subburaj Ilangumaran · 2020 · BMC Cancer
4. Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example
   Shutao Zheng, Shuo He, Yan Liang, Yiyi Tan, Qing Liu, Tao Liu, Xiaomei Lu · 2024 · Molecular Biomedicine
5. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma
   Juan María Roldán‐Romero, Benoit Beuselinck, María Santos, Juan Francisco Rodríguez-Moreno, Javier Lanillos, Bruna Calsina, Ana Gutiérrez, Karin Tang, Núria Laínez, Javier Puente et al. · 2019 · International Journal of Cancer
6. An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types
   Wai Hoong Chang, Alvina Grace Lai · 2020 · BMC Cancer
7. LncRNA DNAJC3-AS1 Regulates Fatty Acid Synthase via the EGFR Pathway to Promote the Progression of Colorectal Cancer
   Yanyan Tang, Rui Tang, Mengtian Tang, Ping Huang, Zhiqiang Liao, Jumei Zhou, Lianqing Zhou, Min Su, Pan Chen, Jiarui Jiang et al. · 2021 · Frontiers in Oncology
8. Molecular and Morphological Changes Induced by Ivosidenib Correlate with Efficacy in Mutant- IDH1 Cholangiocarcinoma
   Elia Aguado-Fraile, Anna M. Tassinari, Yuko Ishii, Carlie Sigel, Maeve Aine Lowery, Lipika Goyal, Camelia Gliser, Liewen Jiang, Shuchi Sumant Pandya, Bin Wu et al. · 2021 · Future Oncology
9. Oncogenic Pathways in Neurodegenerative Diseases
   Luis Varela, María E.R. García-Rendueles · 2022 · International Journal of Molecular Sciences
10. Targeting DEAD ‐box RNA helicases: The emergence of molecular staples
    Sai Kiran Naineni, Francis Robert, Bhushan Nagar, Jerry Pelletier · 2022 · Wiley Interdisciplinary Reviews - RNA
11. Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signaling
    Hongxing Shen, Fengyuan Huang, Xiangmin Zhang, Oluwagbemiga A. Ojo, Yuebin Li, Hoa Quang Trummell, Joshua Charles Anderson, John B. Fiveash, Markus Bredel, Eddy Shih-Hsin Yang et al. · 2022 · Nature Communications
12. Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer
    Aditi Sharma, Lalit Kumar Sharma, Shouvik Kumar Nandy, Nazrana Payal, Shivam Yadav, Celia Bertha Vargas-De-La-Cruz, Md. Khalid Anwer, Haroon Zaman Khan, Tapan Behl, SIMONA GABRIELA BUNGAU · 2023 · Molecules
13. SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2
    Gaurav A. Mehta, Steven P. Angus, Christen A. Khella, Kevin Tong, Pooja Khanna, Shelley A.H. Dixon, Michael Paul Verzi, Gary L. Johnson, Michael L. Gatza · 2021 · npj Breast Cancer
14. A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer
    Regina Cencic, Young Kyuen Im, Sai Kiran Naineni, Mohamed Moustafa-Kamal, Predrag Jovanovic, Valérie Sabourin, Matthew G. Annis, Francis Robert, T.M. Schmeing, Antonis E. Koromilas et al. · 2024 · Proceedings of the National Academy of Sciences
15. Regulatory effects of statins on Akt signaling for prevention of cancers
    Fatemeh Sadat Hosseini, Abdolreza Ahmadi, Prashant Kesharwani, Hossein Hosseini, Amirhossein Sahebkar · 2024 · Cellular Signalling
16. Fentanyl inhibits the progression of gastric cancer through the suppression of MMP-9 via the PI3K/Akt signaling pathway
    Chunlai Li, Yi Qin, Yu Zhong, Yinying Qin, Yi Wei, Li Li, Yubo Xie · 2020 · Annals of Translational Medicine
17. The roles of E3 ligases in Hepatocellular carcinoma.
    Zongdong Yu, Hong Li, Jie Zhu, Haibiao Wang, Xiaofeng Jin · 2022 · PubMed
18. Crosstalk between protein kinases AKT and ERK1/2 in human lung tumor-derived cell models
    Aurimas Stulpinas, Matas Sereika, Aida Vitkevičienė, Aušra Imbrasaitė, Natalija Krestnikova, Audronė Valerija Kalvelytė · 2023 · Frontiers in Oncology
19. On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances
    Yiwu Yan, Su Yeon Yeon, Chen Qian, Sungyong You, Wei Yang · 2021 · International Journal of Molecular Sciences
20. Clinical proteomics towards multiomics in cancer
    Chad J. Creighton · 2022 · Mass Spectrometry Reviews
21. Osthole induces cell cycle arrest and apoptosis in head and neck squamous cell carcinoma by suppressing the PI3K/AKT signaling pathway
    Jing Yang, Xin-Jiang Zhu, Mingzhu Jin, Zhiwei Cao, Yaoyao Ren, Zhaowei Gu · 2019 · Chemico-Biological Interactions
22. Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets
    Meena Jhanwar‐Uniyal, Sabrina L. Zeller, Eris Spirollari, Mohan Das, Simon Jeremy Hanft, Chirag D. Gandhi · 2024 · Cells
23. An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components
    Wai Hoong Chang, Alvina Grace Lai · 2019 · Molecular Medicine
24. In Silico and In Cell Hybrid Selection of Nonrapalog Ligands to Allosterically Inhibit the Kinase Activity of mTORC1
    Raef S. Shams, Akihiro Matsukawa, Yukari Ochi, Yoshihiro Ito, Hideyuki Miyatake · 2021 · Journal of Medicinal Chemistry
25. Exploring the potential of dietary factors and plant extracts as chemopreventive agents in oral squamous cell carcinoma treatment
    Madhav kumar, Abhimanyu Kumar Jha · 2023 · Frontiers in Oral Health
26. Mouse Models for Exploring the Biological Consequences and Clinical Significance of PIK3CA Mutations
    Camilla B. Mitchell, Wayne Allen Phillips · 2019 · Biomolecules
27. PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy
    Zoé Tharin, Corentin Richard, Valentin Dérangère, Alis Ilie, Laurent Arnould, François Ghiringhelli, Romain Boidot, Sylvain Ladoire · 2023 · Scientific Reports
28. Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting
    Claudia Cerella, Mario A. Dicato, Marc F. Diederich · 2023 · Pharmacological Research
29. Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA -Mutant Lung Squamous Cell Carcinoma
    Ruoshi Shi, Ming Li, Vibha Raghavan, Shirley Tam, Michael Cabanero, Nhu‐An Pham, Frances A. Shepherd, Nadeem Moghal, Ming‐Sound Tsao · 2018 · Clinical Cancer Research
30. Integrated Genomic Characterization of the Human Immunome in Cancer
    Yongsheng Li, Todd Triplett, Brandon Burgman, Ming Sun, Daniel James McGrail, Dan Qi, Sachet Shukla, Erxi Wu, Catherine J. Wu, Anna Capasso et al. · 2020 · Cancer Research
31. PIK3CA Mutations in Diffuse Gliomas: An Update on Molecular Stratification, Prognosis, Recurrence, and Aggressiveness
    Cheila Brito, Ana Tomás, Ana Azevedo, Susana Esteves, Manuela Mafra, Lúcia Roque, Marta Pojo · 2022 · Clinical Medicine Insights Oncology
32. Resistance to mutant IDH inhibitors in acute myeloid leukemia: Molecular mechanisms and therapeutic strategies
    Kun Yao, Hua Liu, Shui Yu, Haohao Zhu, Jie Pan · 2022 · Cancer Letters
33. Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties
    Nannan Zhu, Qian Hui Wang, Zhidong Wu, Yan Wang, Mu‐Sheng Zeng, Yan Yuan · 2022 · Journal of Virology
34. Traditional Chinese medicine for transformation of gastric precancerous lesions to gastric cancer: A critical review
    Yi-Lin Zhong, Peng-Qian Wang, Dan-Li Hao, Feng Sui, Fengbin Zhang, Bing Li · 2023 · World Journal of Gastrointestinal Oncology
35. Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
    Katherine E. Hutchinson, Jessica W. Chen, Heidi M. Savage, Thomas J. Stout, Frauke Schimmöller, Javier Cortés, Susan Faye Dent, Nadia Harbeck, William Jacot, Ian E. Krop et al. · 2023 · Genome Medicine
36. Gentisic acid prevents colorectal cancer metastasis via blocking GPR81-mediated DEPDC5 degradation.
    Gui-Ze Feng, Lijie Zhang, Wei-Lian Bao, Jia-hui Ni, Yirui Wang, Yu-Ran Huang, Jiaren Lyv, Xinyue Cao, Tongqing Chen, Keyuan You et al. · 2024 · Phytomedicine
37. HIF-mediated Suppression of DEPTOR Confers Resistance to mTOR Kinase Inhibition in Renal Cancer
    Hong Doan, Alexander Parsons, Shruthi Devkumar, Jogitha Selvarajah, Francesc Miralles, Veronica A. Carroll · 2019 · iScience
38. 2,6-DMBQ is a novel mTOR inhibitor that reduces gastric cancer growth in vitro and in vivo
    Xueyin Zu, Xiaoli Ma, Xiaomeng Xie, Bingbing Lu, Kyle Vaughn Laster, Kangdong Liu, Zigang Dong, Dong Joon Kim · 2020 · Journal of Experimental & Clinical Cancer Research
39. PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition
    Jennifer M. Spangle, Thanh Von, Dean C. Pavlick, Arina Khotimsky, Jean J. Zhao, Thomas M. Roberts · 2020 · Proceedings of the National Academy of Sciences
40. RASSF1A independence and early galectin‐1 upregulation in PIK3CA‐induced hepatocarcinogenesis: new therapeutic venues
    Alexander Scheiter, Katja Evert, Lucas E. Reibenspies, Antonio Cigliano, Katharina Annweiler, Karolina Müller, Laura‐Maria‐Giovanna Pöhmerer, Hongwei Xu, Guofei Cui, Timo Itzel et al. · 2021 · Molecular Oncology
41. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma
    Meena Jhanwar‐Uniyal, Jose F. Dominguez, AVINASH L. MOHAN, Michael E. Tobias, Chirag D. Gandhi · 2021 · Advances in Biological Regulation
42. PI5P4Kα supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition
    Joanna Triscott, Matthias Reist, L KUNG, Francielle Caroline Mosele, Marika Lehner, John Gallon, Archna Ravi, Gurpreet K. Arora, Simone de Brot, Mark R. Lundquist et al. · 2023 · Science Advances
43. Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro
    Valentina Citi, Marzia Del Re, Alma Martelli, Vincenzo Calderone, Maria Cristina Breschi, Romano Danesi · 2018 · Cancer Chemotherapy and Pharmacology
44. Autoimmune Responses in Oncology: Causes and Significance
    Halin Bareke, Pablo Juanes‐Velasco, Alicia Landeira‐Viñuela, Ángela‐Patricia Hernández, Juan Jesús Cruz, Lorena Bellido, Emilio Fonseca, Alfonssina Niebla Cárdenas, Enrique Montalvillo, Rafael Góngora et al. · 2021 · International Journal of Molecular Sciences
45. Pan-cancer analysis of biallelic inactivation in tumor suppressor genes identifies KEAP1 zygosity as a predictive biomarker in lung cancer
    Mark Zucker, Maria Perry, Samuel I. Gould, Arielle Elkrief, Anton Mikhailovich Safonov, Rohit Thummalapalli, Miika M. Mehine, Debyani Chakravarty, Angela Rose Brannon, Marc Ladanyi et al. · 2024 · Cell
46. Unlocking diagnostic potential: A retrospective analysis of GPNMB immunohistochemistry in nearly 1000 surgical pathology specimens
    Huili Li, Andrés Matoso · 2025 · Human Pathology
47. Potential relationship between Sirt3 and autophagy in ovarian cancer (Review)
    Yuchuan Shi, Runhua He, Yang Yu, Yu He, Lei Zhan, Bing Wei · 2020 · Oncology Letters
48. Reciprocal REGγ-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma
    Liangfang Yao, Xuan Yang, Haiyang Zhang, Bo Yang, Xinglong Ma, Tianzhen Wang, Tianyuan Meng, Wenshe Sun, Haibin Wei, Xueqing Ma et al. · 2020 · Oncogene
49. An amino acid-defined diet impairs tumour growth in mice by promoting endoplasmic reticulum stress and mTOR inhibition
    Maurizio Ragni, Chiara Ruocco, Laura Tedesco, Michele O. Carruba, Alessandra Valerio, Enzo Nisoli · 2022 · Molecular Metabolism
50. Landscape of Genetic Mutations in Appendiceal Cancers
    Marian Constantin, Cristina Mătanie, Livia Petrescu, Alexandra Bolocan, Octavian Andronic, Coralia Bleoţu, Mihaela Magdalena Mitache, Sorin Ioan Tudorache, Corneliu Ovidiu Vrâncianu · 2023 · Cancers
51. A protein expression atlas on tissue samples and cell lines from cancer patients provides insights into tumor heterogeneity and dependencies
    Jun Li, Wei Liu, Kamalika Mojumdar, Hong Kim, Zhicheng Zhou, Zhenlin Ju, Shwetha V. Kumar, Patrick Kwok‐Shing Ng, Han Chen, Michael A. Davies et al. · 2024 · Nature Cancer
52. Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients
    Keiichi Hatakeyama, Takeshi Nagashima, Keiichi Ohshima, Sumiko Ohnami, Shumpei Ohnami, Yuji Shimoda, Akane Naruoka, Koji Maruyama, Akira Iizuka, Tadashi Ashizawa et al. · 2020 · Cancer Science
53. Integrated multi-omics analysis and machine learning developed a prognostic model based on mitochondrial function in a large multicenter cohort for Gastric Cancer
    Yimeng Ma, Jingjing Jin, Zixuan Xue, Jungang Zhao, Weiyang Cai, Wanli Zhang · 2024 · Journal of Translational Medicine
54. Adaptations of membrane trafficking in cancer and tumorigenesis
    Emma Evergren, Ian Geoffrey Mills, Grace Kennedy · 2024 · Journal of Cell Science
55. Effect of PI3K/Akt/mTOR signaling pathway on JNK3 in Parkinsonian rats
    Ying Chen, Xiaozhen Zheng, Ying Wang, Song Junjie · 2018 · Experimental and Therapeutic Medicine
56. Mutant TP53 switches therapeutic vulnerability during gastric cancer progression within interleukin-6 family cytokines
    Anne Huber, Amr H. Allam, Christine Dijkstra, Stefan Thiem, Jennifer Huynh, Ashleigh R. Poh, Joshua Konecnik, Saumya P. Jacob, Rita A. Busuttil, Yang Liao et al. · 2024 · Cell Reports
57. Body fatness and mTOR pathway activation of breast cancer in the Women’s Circle of Health Study
    Ting‐Yuan David Cheng, Angela R. Omilian, Song Yao, Pamela V. Sanchez, Latasia Z. Polk, Weizhou Zhang, Susmita Datta, Wiam Bshara, Rochelle Payne Ondracek, Warren Davis et al. · 2020 · npj Breast Cancer
58. Hydroxysafflor Yellow A Attenuates Hydrogen Peroxide‐Induced Oxidative Damage on Human Umbilical Vein Endothelial Cells
    Yuefeng Xie, Yan Guo, ShiDong Cao, Miaomiao Xue, ZhaoYue Fan, Chengxian Gao, Bo Jin · 2020 · Evidence-based Complementary and Alternative Medicine
59. The clinical applications of The Cancer Genome Atlas project for bladder cancer
    Chad J. Creighton · 2018 · Expert Review of Anticancer Therapy
60. A novel glycosylated indolocarbazole derivative LCS1269 effectively inhibits growth of human cancer cells in vitro and in vivo through driving of both apoptosis and senescence by inducing of DNA damage and modulating of AKT/mTOR/S6K and ERK pathways
    Nikolay N. Kalitin, Lidia V. Ektova, Natalia Kostritsa, Anastasia S. Sivirinova, Aleksandr Kostarev, Galina B. Smirnova, Yulia A. Borisova, И. С. Голубева, Elisaveta V. Ermolaeva, Maria Andreevna Vergun et al. · 2022 · Chemico-Biological Interactions
61. Oncogenic signaling-mediated regulation of chromatin during tumorigenesis
    Jahangir Alam, Md Nazmul Huda, Alan J. Tackett, Sayem Miah · 2023 · Cancer and Metastasis Reviews
62. Organismal roles for the PI3Kα and β isoforms: their specificity, redundancy or cooperation is context-dependent.
    S. Arcucci, Fernanda Ramos-Delgado, C. Cayron, N. Therville, M. Gratacap, C. Basset, B. Thibault, J. Guillermet-Guibert · 2021 · Biochemical Journal
63. Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs
    Simona Punzi, Marina B. Melixetian, Laura Riva, Federica Marocchi, Giancarlo Pruneri, Carmen Criscitiello, Franco Orsi, Lorenzo Spaggiari, Monica Casiraghi, Paolo Della Vigna et al. · 2019 · Cells
64. Linear ubiquitination of PTEN impairs its function to promote prostate cancer progression
    Yanmin Guo, Jianfeng He, Hailong Zhang, Ran Chen, Lian Li, Xiaojia Liu, Caihu Huang, Zhe Qiang, Zihan Zhou, Yanli Wang et al. · 2022 · Oncogene
65. Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma
    Huey-Jen L. Lin, Yingguang Liu, Kailey P. Caroland, Jiayuh Lin · 2023 · Cancers
66. MAD2 activates IGF1R/PI3K/AKT pathway and promotes cholangiocarcinoma progression by interfering USP44/LIMA1 complex
    Wangjie Jiang, Xiao Feng Yang, Kuangheng Shi, Yaodong Zhang, Xiaoli Shi, Jifei Wang, Yuming Wang, Anlan Chenyan, Jijun Shan, Yirui Wang et al. · 2023 · Oncogene
67. 9S1R nullomer peptide induces mitochondrial pathology, metabolic suppression, and enhanced immune cell infiltration, in triple-negative breast cancer mouse model
    Nilufar Ali, Cody L. Wolf, Swarna Kanchan, Shivakumar R. Veerabhadraiah, Laura Bond, Matthew W. Turner, Cheryl L. Jorcyk, Greg Hampikian · 2023 · Biomedicine & Pharmacotherapy
68. PLS3 predicts poor prognosis in pancreatic cancer and promotes cancer cell proliferation via PI3K/AKT signaling
    Zechang Xin, Duguang Li, Feiyu Mao, Yan Du, Xiaodong Wang, Peng Xu, Zhennan Li, Jianjun Qian, Jie J. Yao · 2020 · Journal of Cellular Physiology
69. Androgen receptor and uterine histoarchitecture in a PCOS rat model
    Gisela Soledad Bracho, Acosta M Virginia, Gabriela A. Altamirano, María V. Tschopp, Luque Enrique H, Laura Kass, Verónica L. Bosquiazzo · 2020 · Molecular and Cellular Endocrinology
70. Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models
    Petros A. Tyrakis, Domen Kampjut, Georgina F. Steele, H. Jonathan G. Lindström, Deborah Chirnomas, Benjamin David Hopkins, Marcus DaSilva Goncalves, Siddhartha Mukherjee, Lewis C. Cantley, Oliver D.K. Maddocks · 2025 · British Journal of Cancer
71. Survival prediction based on the gene expression associated with cancer morphology and microenvironment in primary central nervous system lymphoma
    Yasuo Takashima, Atsushi Kawaguchi, Junya Fukai, Yasuo Iwadate, Koji Kajiwara, Hiroaki Hondoh, Ryuya Yamanaka · 2021 · PLoS ONE
72. PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
    Ilenia Migliaccio, Marta Paoli, Emanuela Risi, Chiara Biagioni, Laura Biganzoli, Matteo Benelli, Luca Malorni · 2022 · npj Breast Cancer
73. Development of PI3Kα inhibitors for tumor therapy
    Wenqing Jia, Shuyu Luo, Han Wen Guo, Dexin Kong · 2022 · Journal of Biomolecular Structure and Dynamics
74. Interfering with the Ubiquitin-Mediated Regulation of Akt as a Strategy for Cancer Treatment
    Elena Paccosi, Alessio Balzerano, Luca Proietti‐De‐Santis · 2023 · International Journal of Molecular Sciences
75. An Overview of Renal Cell Carcinoma Hallmarks, Drug Resistance, and Adjuvant Therapies
    JOSIELE DA SILVA PRADE, RUAN SOARES DE SOUZA, CAMILA MEDIANEIRA DA SILVA D’ÁVILA, THAYLINE CORREIA DA SILVA, ISADORA CASSEL LIVINALLI, Ana Clara Zanini Bertoncelli, FERNANDA KRAPF SACCOL, Tallys de Oliveira Mendes, LARISSA GINDRI WENNING, Theodoro da Rosa Salles et al. · 2023 · Cancer Diagnosis & Prognosis
76. Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?
    Célia Cintas, Julie Guillermet‐Guibert · 2018 · Frontiers in Oncology
77. Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment
    Ximena Rosas-Plaza, Gerda de Vries, Gert Jan Meersma, Albert J.H. Suurmeijer, Jourik A. Gietema, Marcel A.T.M. van Vugt, Steven de Jong · 2019 · Molecular Cancer Therapeutics
78. Autocrine CXCL8-dependent invasiveness triggers modulation of actin cytoskeletal network and cell dynamics
    Andrea Antonosante, Laura Brandolini, Michele d’Angelo, Elisabetta Benedetti, Vanessa Castelli, Mattia Del Maestro, Sabino Luzzi, Antonio Giordano, Annamaria Cimini, Marcello Allegretti · 2020 · Aging
79. Identification of the Mutational Landscape of Gynecological Malignancies
    Suresh Chava, Romi Gupta · 2020 · Journal of Cancer
80. Targeting amino acid metabolism to inhibit gastric cancer progression and promote anti-tumor immunity: a review
    Yuchun Jiang, Tao Qing, Xuehan Qiao, Yufei Yang, Peng Chen, Miao Han, Kebin Dong, Wei Zhang, Min Xu, Deqiang Wang et al. · 2025 · Frontiers in Immunology
81. miR‑654‑5p inhibits autophagy by targeting ATG7 via mTOR signaling in intervertebral disc degeneration
    Shanzheng Wang, Yudong Guo, Xuejun Zhang, Chen Wang · 2021 · Molecular Medicine Reports
82. Integrated Genomic and Transcriptomic Analysis reveals key genes for predicting dual-phenotype Hepatocellular Carcinoma Prognosis
    Yaobang Wang, Xi Wang, Xiaoliang Huang, Jie Zhang, Junwen Hu, Yapeng Qi, Bang‐De Xiang, Qiuyan Wang · 2021 · Journal of Cancer
83. Machine learning approach informs biology of cancer drug response
    Eliot Y. Zhu, Adam J. Dupuy · 2022 · BMC Bioinformatics
84. Involvement of the p53‐p16/RB pathway control mechanism in early‐stage carcinogenesis in head and neck squamous cell carcinoma
    Taisuke Mori · 2022 · Pathology International
85. Uncovering the mechanism of Kang-ai injection for treating intrahepatic cholangiocarcinoma based on network pharmacology, molecular docking, and in vitro validation
    Fei Song, Changliang Lu, Chenggui Wang, Chen-Wei Hu, Yu Xin Zhang, Tianlun Wang, Lu Han, Zhong Chen · 2023 · Frontiers in Pharmacology
86. Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies
    Michelle V. Dietz, Job P. van Kooten, Marthe S. Paats, J.G.J.V. Aerts, Cornelis Kees Verhoef, Eva V. E. Madsen, Hendrikus Jan Dubbink, Jan H. von der Thüsen · 2023 · ESMO Open
87. Biomedical engineering targeting cancer stem cells to reinforce cancer therapy
    Shumin Sun, Nailin Yang, Zifan Pei, Fei Gong, Liang Cheng · 2025 · Coordination Chemistry Reviews
88. Serum and Glucocorticoid-Inducible Kinase 1 (SGK1) in NSCLC Therapy
    Ilaria Guerriero, Gianni Monaco, Vincenzo Coppola, Arturo Orlacchio · 2020 · Pharmaceuticals
89. Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma
    Antonio Mulero‐Sánchez, Christel F. A. Ramirez, Aimée du Chatinier, Hui Wang, Sofie J. I. Koomen, Ji‐Ying Song, Marnix H. P. de Groot, Cor Lieftink, Astrid R. Bosma, Artur M Burylo et al. · 2023 · Molecular Oncology
90. Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in�vivo and in�vitro by inhibiting the PI3K/AKT/mTOR signaling pathway
    Zhi Teng, Shi-juan Xu, Qin Lei · 2019 · Oncology Reports · Retracted
91. Functional impact and targetability of PI3KCA , GNAS , and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation
    Florence Choo, Igor Odintsov, Kevin Nusser, Katelyn S. Nicholson, Lara Emily Davis, Christopher L. Corless, Linda Stork, Romel Somwar, Marc Ladanyi, Jessica L. Davis et al. · 2022 · Molecular Case Studies
92. Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells
    Heinemann, Luca, Möllers, Klara Maria, Ahmed, Helal Mohammed Mohammed, Wei, Lanying, Sun, Kaiyan, Nimmagadda, Subbaiah Chary, Frank, Daria, Baumann, Anja, Poos, Alexandra M., Dugas, Martin et al. · 2022 · Frontiers in Oncology
93. Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
    Maruyama, Kohei, Shimizu, Yuki, Nomura, Yumi, Oh-hara, Tomoko, Takahashi, Yuki, Nagayama, Satoshi, Fujita, Naoya, Katayama, Ryohei · 2025 · npj Precision Oncology
94. Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities
    Maryam Yousefi, Gábor Zoltán Boross, Carly V. Weiss, Christopher W. Murray, Jess D. Hebert, Hongchen Cai, Emily L. Ashkin, Saswati Karmakar, Laura Andrejka, Leo C. Chen et al. · 2022 · Cancer Research
95. Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse
    James R. W. Conway, Sean C. Warren, Young-Kyung Lee, Andrew T McCulloch, Astrid Magenau, Victoria Lee, Xanthe L. Metcalf, Janett Stoehr, Katharina Haigh, Lea Abdulkhalek et al. · 2023 · Science Advances
96. Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition
    Juan María Roldán‐Romero, Carlos Valdivia, María Santos, Javier Lanillos, Pablo Maroto, Geòrgia Anguera, Bruna Calsina, Ángel M. Martínez‐Montes, María Monteagudo, Sara Mellid et al. · 2023 · International Journal of Cancer
97. Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1
    Heng Du, Yu Chi Yang, Heng-Jia Liu, Min Yuan, John M. Asara, Kwok‐Kin Wong, Elizabeth P. Henske, Mallika Singh, David J. Kwiatkowski · 2023 · Journal of Clinical Investigation
98. Metabolic Interplay in the Tumor Microenvironment: Implications for Immune Function and Anticancer Response
    Reem Youssef, Rohan Maniar, Jaffar Khan, Hector A. Mesa · 2023 · Current Issues in Molecular Biology
99. Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer
    Yue Wang, Hanbing Wang, Tao Shi, Xueru Song, Xin Zhang, Yue Zhang, Xuan Wang, Keying Che, Yuting Luo, Lixia Yu et al. · 2024 · EMBO Molecular Medicine
100. Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics
     Célia Cintas, Thibaut Douché, Nicole Therville, Silvia Arcucci, Fernanda Ramos‐Delgado, Céline Basset, Benoît Thibault, Julie Guillermet‐Guibert · 2018 · Cancers